Olumiant for hair loss represents a significant advance in the treatment of severe alopecia areata, offering adults in the UK a licensed oral therapy where few systemic options previously existed. Baricitinib — the active ingredient in Olumiant — is a JAK inhibitor that targets the autoimmune processes driving hair follicle damage. Approved by both the MHRA and EMA specifically for severe alopecia areata, it is available on the NHS in England subject to NICE criteria. This article explains how Olumiant works, what to expect during treatment, its safety profile, NHS eligibility, and the alternatives available for different types of hair loss.

What Is Olumiant and How Does It Work for Hair Loss?

Olumiant (baricitinib) is a JAK1/JAK2 inhibitor licensed by the MHRA and EMA for severe alopecia areata in adults, suppressing the autoimmune signalling that damages hair follicles to allow regrowth.

Olumiant is the brand name for baricitinib, a medication originally developed and licensed for the treatment of moderate-to-severe rheumatoid arthritis. It has since been approved by both the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of severe alopecia areata in adults aged 18 years and over — one of the first systemic oral treatments to receive this specific licence in the UK.

Alopecia areata is an autoimmune condition in which the immune system mistakenly attacks hair follicles, leading to patchy or, in severe cases, complete hair loss across the scalp (alopecia totalis) or entire body (alopecia universalis). Baricitinib works by inhibiting Janus kinase (JAK) enzymes — specifically JAK1 and JAK2 — which play a central role in the inflammatory signalling pathways that drive this autoimmune attack. By blocking these enzymes, baricitinib reduces the immune-mediated damage to hair follicles, allowing hair regrowth to occur.

Not sure if this is normal? Chat with one of our pharmacists →

It is important to understand that Olumiant does not cure alopecia areata. Rather, it suppresses the underlying immune activity responsible for hair loss. Clinical trials — the BRAVE-AA1 and BRAVE-AA2 studies, published in the New England Journal of Medicine (2022) — demonstrated that a significant proportion of patients treated with baricitinib 4 mg daily achieved substantial scalp hair regrowth compared to placebo after 36 weeks. These findings supported its regulatory approval specifically for severe alopecia areata, defined as loss of 50% or more of scalp hair (SALT score ≥50).

The licensed indication is for adults (≥18 years) only. For full prescribing detail, refer to the Olumiant Summary of Product Characteristics (SmPC) available on the electronic Medicines Compendium (emc) and the EMA European Public Assessment Report (EPAR).

What to Expect During Treatment: Dosage and Timeline

The standard licensed dose is 4 mg once daily, with visible hair regrowth typically beginning between 3 and 6 months; relapse is common if treatment is stopped, as baricitinib does not cure the underlying condition.

Olumiant for alopecia areata is taken orally, once daily, as a tablet. The licensed dose for this indication in most adults is 4 mg once daily. In line with the SmPC, a lower dose of 2 mg once daily may be more appropriate for patients with certain risk factors (for example, older adults or those at higher risk of adverse effects), and de-escalation to 2 mg may be considered once an adequate response has been established and maintained at 4 mg.

Experiencing these side effects? Our pharmacists can help you navigate them →

Dose adjustments are required in renal impairment: the SmPC advises caution and dose reduction in moderate renal impairment, and baricitinib is not recommended in severe renal impairment. It is not recommended in severe hepatic impairment. Patients should inform their prescriber of all existing medical conditions before starting treatment.

Drug interactions: Concomitant use of strong OAT3 inhibitors (such as probenecid) can increase baricitinib exposure and may require dose reduction or avoidance — patients should ensure their prescriber and pharmacist are aware of all medicines they are taking, including over-the-counter products.

Patients should be aware that hair regrowth is not immediate. Most clinical evidence suggests that meaningful regrowth typically begins to become visible between 3 and 6 months of consistent treatment. In the pivotal trials, the proportion of patients achieving clinically significant regrowth continued to increase up to and beyond 36 weeks. Patience and adherence to treatment are therefore essential — stopping treatment prematurely is likely to result in hair loss returning, as the medication does not alter the underlying autoimmune predisposition.

Once treatment is discontinued, relapse is common. There is currently no established guidance on the optimal duration of therapy, and decisions about continuing, adjusting, or stopping treatment should always be made in consultation with a dermatologist.

Monitoring: Before starting treatment, baseline assessments should include a full blood count (FBC), liver function tests (LFTs), renal function, and screening for tuberculosis (TB), hepatitis B, and hepatitis C. A fasting lipid profile should be checked at approximately 12 weeks after starting treatment and periodically thereafter. Treatment should not be initiated if blood count values fall below the thresholds specified in the SmPC (for example, low neutrophil count, low lymphocyte count, or low haemoglobin). Regular monitoring appointments are required throughout treatment.

Vaccinations: Live vaccines should not be given during treatment with baricitinib. Patients should ensure their immunisations — including the shingles (herpes zoster) vaccine — are up to date before starting treatment. Discuss this with your prescriber or GP in advance.

If a serious infection develops during treatment, patients should pause baricitinib and seek prompt medical review. Patients should:

• Attend all scheduled follow-up appointments

• Report any new symptoms promptly to their healthcare team

• Avoid stopping the medication suddenly without medical advice

• Understand that individual responses to treatment vary considerably

Some patients may experience only partial regrowth, while others achieve near-complete restoration of hair. Managing expectations from the outset is an important part of the treatment conversation.

Risks, Side Effects and MHRA Safety Considerations

Serious risks include infections, major cardiovascular events, venous thromboembolism, and potential malignancy; the MHRA restricts JAK inhibitor use in high-risk groups unless no suitable alternative is available.

As with all JAK inhibitors, Olumiant carries a range of potential side effects and safety considerations that patients and prescribers must carefully weigh. The MHRA has issued Drug Safety Update guidance (2023) highlighting important risks associated with the JAK inhibitor class as a whole, and these apply to baricitinib.

Common side effects reported in clinical trials include:

• Upper respiratory tract infections (such as colds and sinusitis)

• Urinary tract infections

• Nausea

• Elevated cholesterol levels

• Acne or skin reactions

More serious risks that require careful monitoring include:

• Serious infections: JAK inhibitors suppress immune function, increasing susceptibility to bacterial, viral (including herpes zoster/shingles), fungal, and opportunistic infections. Patients must be screened for tuberculosis (TB) and hepatitis B and C before starting treatment.

• Cardiovascular events: The MHRA and EMA have highlighted an increased risk of major adverse cardiovascular events (heart attack, stroke) associated with JAK inhibitor use, particularly in patients with existing cardiovascular risk factors.

• Venous thromboembolism (VTE): An increased risk of deep vein thrombosis and pulmonary embolism has been observed with JAK inhibitors.

• Malignancy: There is a potential increased risk of certain cancers, including lymphoma and non-melanoma skin cancer, with long-term use.

• Haematological changes: Reductions in certain blood cell counts may occur, necessitating regular blood monitoring. Treatment should not be initiated below the blood count thresholds specified in the SmPC.

MHRA class restriction for high-risk groups: In accordance with MHRA guidance, baricitinib and other JAK inhibitors should be used in patients aged 65 years or over, long-term smokers, and those with a history of or significant risk factors for cardiovascular disease, malignancy, or VTE only when no suitable alternative treatment is available. Prescribers and patients should discuss these risks carefully before starting treatment.

Vaccinations: Live vaccines must not be administered during treatment. Patients should ensure all immunisations, including the shingles vaccine, are up to date before beginning baricitinib.

Reproductive safety: Baricitinib is contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 1 week after the last dose (verify the current SmPC for the most up-to-date interval). Breastfeeding is not recommended during treatment or for a defined period after the last dose, as specified in the SmPC. Patients should discuss family planning with their prescriber before starting treatment.

Patients should contact their GP or specialist promptly if they develop signs of infection, chest pain, breathlessness, or leg swelling.

Reporting side effects: If you experience a suspected side effect from Olumiant, you are encouraged to report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk. Reporting helps the MHRA monitor the safety of medicines in the UK.

Who Is Eligible for Olumiant on the NHS?

NICE recommends baricitinib for adults with severe alopecia areata (SALT score ≥50), initiated by a consultant dermatologist, with treatment stopped at 36 weeks if a SALT score of 20 or less is not achieved.

Access to Olumiant (baricitinib) for alopecia areata on the NHS in England is governed by guidance from the National Institute for Health and Care Excellence (NICE). NICE has published Technology Appraisal guidance recommending baricitinib as an option for treating severe alopecia areata in adults, subject to specific criteria. Patients and clinicians should refer to the current NICE Technology Appraisal for baricitinib in severe alopecia areata (available at nice.org.uk) for the definitive eligibility criteria and stopping rules, as guidance may be updated.

To be eligible under NICE guidance, patients must generally meet the following conditions:

• They have severe alopecia areata, defined as 50% or more scalp hair loss, as assessed using the Severity of Alopecia Tool (SALT score of ≥50)

• Treatment is initiated and supervised by a consultant dermatologist with experience in managing alopecia areata

• The manufacturer provides baricitinib at the agreed commercial access arrangement price

NICE guidance specifies that treatment should be reviewed at 36 weeks. If the patient has not achieved a SALT score of 20 or less (i.e., 80% or more scalp hair coverage) at this point, treatment should be stopped, as this threshold indicates a clinically meaningful response.

It is worth noting that NICE guidance applies specifically to England. Patients in Scotland should consult the Scottish Medicines Consortium (SMC) for local guidance; patients in Wales and Northern Ireland should contact their respective national health authority, as recommendations may differ.

Patients who do not meet NHS eligibility criteria may wish to discuss private treatment options with a dermatologist, though costs can be considerable. A GP referral to a dermatology service is the appropriate first step for anyone seeking assessment.

Alternatives to Olumiant for Hair Loss in the UK

Alternatives for alopecia areata include topical or intralesional corticosteroids, topical immunotherapy (DPCP), and ritlecitinib (Litfulo), which is licensed for patients aged 12 and over; Olumiant has no licensed role in androgenetic alopecia.

Olumiant is not the only treatment option available for alopecia areata or other forms of hair loss in the UK. The most appropriate treatment depends on the type, severity, and duration of hair loss, as well as individual patient factors.

For alopecia areata, other treatment options include:

• Topical or intralesional corticosteroids: Often used as a first-line treatment for patchy alopecia areata, these reduce local inflammation around hair follicles. They are generally more suitable for limited or mild disease.

• Topical immunotherapy (diphencyprone/DPCP): Available in specialist dermatology centres, this involves sensitising the scalp to a chemical agent to modulate the immune response. It can be effective for extensive disease but requires regular clinic visits. Other contact sensitisers such as squaric acid dibutyl ester (SADBE) and dithranol are used in some specialist centres, though evidence and availability vary.

• Systemic corticosteroids: Sometimes used short-term in rapidly progressive or extensive disease, though long-term use is limited by side effects.

• Topical minoxidil: Widely used to promote hair growth and may be used as an adjunct therapy. It is available over the counter and is licensed for androgenetic alopecia; its use in alopecia areata is off-label.

• Oral minoxidil: Used off-label for hair loss in some specialist settings. Because it is unlicensed for this indication, it carries potential systemic side effects (including cardiovascular effects) and should only be considered under specialist supervision with appropriate monitoring.

• Ritlecitinib (Litfulo): Another JAK inhibitor (TEC/JAK3 inhibitor) licensed for severe alopecia areata in patients aged 12 years and over, offering an alternative for those who cannot tolerate or do not respond to baricitinib. NHS access in England is subject to a separate NICE Technology Appraisal for ritlecitinib — patients and clinicians should refer to the current NICE guidance (available at nice.org.uk) for eligibility and stopping criteria. Access in Scotland is subject to SMC advice.

For androgenetic alopecia (male or female pattern hair loss), which is a separate and far more common condition, Olumiant has no licensed indication and there is no evidence supporting its use for this purpose. Options for androgenetic alopecia include finasteride, topical minoxidil, and hair transplant surgery.

Patients experiencing significant hair loss of any kind are encouraged to seek a GP referral for accurate diagnosis before pursuing any treatment, as the underlying cause determines the most appropriate management pathway. The British Association of Dermatologists and the NHS website provide further patient information on alopecia areata and available treatments.

Frequently Asked Questions